Compare Stocks

→ Do This Today BEFORE Biden Wins in November (From Stansberry Research) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANEB Anebulo Pharmaceuticals	$3.01 +0.3%	$2.77	$1.62 ▼ $4.05	$77.15M	-0.98	5,323 shs	7,397 shs
ENLV Enlivex Therapeutics	$1.50 -1.3%	$2.88	$1.15 ▼ $4.59	$29.20M	1.22	365,107 shs	40,709 shs
IMPL Impel Pharmaceuticals		$0.27	$0.02 ▼ $4.20	$956K	1.17	682,655 shs	720,000 shs
MYNZ Mainz Biomed	$0.66	$0.95	$0.64 ▼ $6.00	N/A	0.28	156,051 shs	56,645 shs

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANEB Anebulo Pharmaceuticals	-0.33%	-3.85%	+10.70%	+20.97%	+30.43%
ENLV Enlivex Therapeutics	-3.18%	-6.17%	-62.75%	-45.71%	-46.67%
IMPL Impel Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	-98.35%
MYNZ Mainz Biomed	-8.47%	-13.87%	-33.43%	-38.41%	-87.25%

Trump’s “Tax Free” Retirement Strategy (Ad)

Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.

Protect your retirement savings from the inevitable devaluation of the dollar…

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANEB Anebulo Pharmaceuticals	2.8019 of 5 stars	3.5	5.0	0.0	0.0	2.8	1.7	0.0
ENLV Enlivex Therapeutics	2.6387 of 5 stars	3.5	5.0	0.0	0.0	0.6	0.8	1.3
IMPL Impel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MYNZ Mainz Biomed	1.9348 of 5 stars	3.3	3.0	0.0	0.0	2.9	0.0	0.0

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANEB Anebulo Pharmaceuticals	3.00	Buy	$6.67	121.48% Upside
ENLV Enlivex Therapeutics	3.00	Buy	$7.00	366.67% Upside
IMPL Impel Pharmaceuticals	N/A	N/A	N/A	N/A
MYNZ Mainz Biomed	2.50	Moderate Buy	$6.00	809.09% Upside

Current Analyst Ratings

Latest IMPL, ANEB, ENLV, and MYNZ Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/23/2024	ENLV Enlivex Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
4/12/2024	ENLV Enlivex Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $7.00
4/12/2024	MYNZ Mainz Biomed	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral
3/6/2024	MYNZ Mainz Biomed	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $3.00

(Data available from 5/10/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANEB Anebulo Pharmaceuticals	N/A	N/A	N/A	N/A	$0.41 per share	N/A
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	$1.62 per share	N/A
IMPL Impel Pharmaceuticals	$20.99M	0.00	N/A	N/A	($1.86) per share	0.00
MYNZ Mainz Biomed	$900K	N/A	N/A	N/A	$0.27 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANEB Anebulo Pharmaceuticals	-$11.73M	-$0.42	N/A	N/A	N/A	N/A	-109.40%	-98.40%	N/A
ENLV Enlivex Therapeutics	-$29.07M	-$1.56	N/A	N/A	N/A	N/A	-71.00%	-59.08%	6/21/2024 (Estimated)
IMPL Impel Pharmaceuticals	-$106.31M	-$3.13	N/A	N/A	N/A	-353.93%	N/A	-127.43%	N/A
MYNZ Mainz Biomed	-$26.30M	-$1.64	N/A	∞	N/A	-2,934.82%	-488.05%	-145.77%	5/21/2024 (Estimated)

Latest IMPL, ANEB, ENLV, and MYNZ Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/9/2024	Q4 2023	MYNZ Mainz Biomed	N/A	-$0.24	-$0.24	-$0.24	N/A	$0.22 million
3/29/2024	Q4 2023	ENLV Enlivex Therapeutics	N/A	-$0.48	-$0.48	-$0.48	N/A	N/A
2/13/2024	Q2 2024	ANEB Anebulo Pharmaceuticals	-$0.11	-$0.11	N/A	-$0.11	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANEB Anebulo Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	N/A
IMPL Impel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MYNZ Mainz Biomed	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANEB Anebulo Pharmaceuticals	N/A	6.72	6.72
ENLV Enlivex Therapeutics	N/A	5.57	5.57
IMPL Impel Pharmaceuticals	N/A	0.19	0.13
MYNZ Mainz Biomed	0.36	0.97	0.91

Ownership

Institutional Ownership

Company	Institutional Ownership
ANEB Anebulo Pharmaceuticals	28.40%
ENLV Enlivex Therapeutics	1.02%
IMPL Impel Pharmaceuticals	73.88%
MYNZ Mainz Biomed	N/A

Insider Ownership

Company	Insider Ownership
ANEB Anebulo Pharmaceuticals	85.90%
ENLV Enlivex Therapeutics	12.28%
IMPL Impel Pharmaceuticals	6.20%
MYNZ Mainz Biomed	N/A

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ANEB Anebulo Pharmaceuticals	2	25.63 million	3.61 million	Not Optionable
ENLV Enlivex Therapeutics	50	18.60 million	16.32 million	Optionable
IMPL Impel Pharmaceuticals	160	23.90 million	22.42 million	Not Optionable
MYNZ Mainz Biomed	65	N/A	N/A	Not Optionable

IMPL, ANEB, ENLV, and MYNZ Headlines

Source	Headline
	EQS-News: Mainz BioMed N.V.: Mainz Biomed präsentiert Ergebnisse der Darmkrebsfrüherkennungsstudie eAArly DETECT auf der Digestive Disease Week 2024 finanznachrichten.de - May 7 at 11:07 AM
	EQS-News: Mainz Biomed präsentiert Ergebnisse der Darmkrebsfrüherkennungsstudie eAArly DETECT auf der Digestive Disease Week 2024 onvista.de - May 7 at 11:06 AM
	Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C. globenewswire.com - May 7 at 8:01 AM
	Mainz Biomed (NASDAQ:MYNZ) Shares Down 3.7% americanbankingnews.com - May 4 at 3:16 AM
	Strictly Come Dancing's Shirley Ballas shares important cancer update to fans uk.news.yahoo.com - April 30 at 12:19 PM
	Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic globenewswire.com - April 25 at 9:29 AM
	Mainz Biomed N.V. (MYNZ) Price Target Decreased by 9.09% to 5.10 msn.com - April 17 at 2:35 AM
	The Pharmaceutical Industry Finds Itself At A Historical Crossroads finance.yahoo.com - April 10 at 1:44 PM
	MYNZ Stock Earnings: Mainz Biomed Beats EPS, Misses Revenue for Q4 2023 investorplace.com - April 9 at 11:01 PM
	EQS-News: Mainz Biomed Reports Full Year 2023 Financial Results markets.businessinsider.com - April 9 at 1:06 PM
	Mainz Biomed gibt die Finanzergebnisse für das Jahr 2023 bekannt anlegerplus.de - April 9 at 1:06 PM
	Mainz Biomed Reports Full Year 2023 Financial Results globenewswire.com - April 9 at 8:01 AM
	MYNZ Mainz Biomed N.V. seekingalpha.com - April 5 at 6:13 PM
	Pharma's Post-Pandemic Story To Unlock A Cancer-Free Era benzinga.com - April 2 at 12:37 PM
	EQS-News: Mainz Biomed: Webinar zur Darmkrebs-Früherkennung – Neue labordiagnostische Optionen onvista.de - March 19 at 2:03 PM
	EQS-News: Mainz Biomed organisiert Informationsveranstaltung HALLO DOC! zu Innovationen in der Darmkrebsbehandlung (deutsch) boerse-online.de - March 19 at 2:03 PM
	EQS-News: Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment markets.businessinsider.com - March 19 at 9:00 AM
	Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment globenewswire.com - March 19 at 8:01 AM
	EQS-News: Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options markets.businessinsider.com - March 18 at 12:56 PM
	Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options globenewswire.com - March 18 at 8:01 AM
	Mainz BioMed NV: Mainz Biomed Presents ColoAlert at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations finanznachrichten.de - March 12 at 8:41 AM
	Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations globenewswire.com - March 12 at 8:01 AM
	What Makes Mainz Biomed NV (MYNZ) a New Buy Stock zacks.com - March 8 at 1:01 PM
	Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic globenewswire.com - March 5 at 8:01 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

3 Stocks Leading the U.S. Agriculture Comeback
April 26, 2024 10:10 AM
View 3 Stocks Leading the U.S. Agriculture Comeback
How to Use Put Debit Spreads to Profit From Falling Stocks
April 26, 2024 9:30 AM
View How to Use Put Debit Spreads to Profit From Falling Stocks
Stock market today: Alphabet and Microsoft help Wall Street clinch its best week in nearly 6 months
April 26, 2024 3:21 AM
View Stock market today: Alphabet and Microsoft help Wall Street clinch its best week in nearly 6 months
Seagate Technology Warns Cloud Demand is Heating Up
April 30, 2024 10:10 AM
View Seagate Technology Warns Cloud Demand is Heating Up
It’s Time to Buy Into the Super Micro Computer Stock Implosion
April 22, 2024 12:33 PM
View It’s Time to Buy Into the Super Micro Computer Stock Implosion

All Headlines

Company Descriptions

Anebulo Pharmaceuticals

NASDAQ:ANEB

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

Enlivex Therapeutics

NASDAQ:ENLV

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Impel Pharmaceuticals

NASDAQ:IMPL

Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. The company was incorporated in 2008 and is headquartered in Seattle, Washington.

Mainz Biomed

NASDAQ:MYNZ

Mainz Biomed N.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics. It offers ColoAlert, a colorectal cancer screening stool-based deoxyribonucleic acid test; and PancAlert, a product candidate for a pancreatic cancer screening test. The company has a research collaboration with Microba Life Sciences to discover and develop novel therapeutics for major diseases. The company was founded in 2008 and is based in Mainz, Germany.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial